Medicine
Bortezomib 3.5 mg/3.5 mL powder for injection
Bortezomib 3.5 mg/3.5 mL powder for injection is a generic prescription medicine for intravenous, subcutaneous use, made by 5 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Unopened vials may be stored at controlled room temperature 25°C (77°F)…
Key facts
- Active ingredient (INN)
- Bortezomib
- Brand
- Sold under the generic name
- Strength
- 3.5 mg/3.5 mL
- Dosage form
- Powder for injection
- Route
- Intravenous, subcutaneous
- Packs
- 1 vial and 3 more
- Manufacturers
- Zydus LifesciencesIndiaNovadoz PharmaceuticalsIndiaBluePoint LaboratoriesSinteticaSomerset Therapeutics
- Origin register
- US FDA, United States
- Storage
- Unopened vials may be stored at controlled room temperature 25°C (77°F), excursions permitted from 15 to 30°C (59 to 86°F). Retain in original package to protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XG01 Bortezomib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 2 May 2022
- Identifiers
- RxCUI 402243DailyMed set ID 582c7c0d-fa25-4586-8157-a1e2653d72d9, dc737d3d-2a4e-448a-ad70-e013065c411c, d41340c2-7fe8-42b2-aaa5-c9f9b0e9b50e +3NDC 70771-1708, 70069-836, 72205-183 +3Application ANDA210204, ANDA211898, ANDA209622
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 3.5 mL in 1 vial, single-dose | 70710-1411-1 | Zydus LifesciencesIndia | 2 May 2022 |
| 1 vial, single-dose in 1 carton / 3.5 mL in 1 vial, single-dose | 70771-1708-1 | Zydus LifesciencesIndia | 2 May 2022 |
| 1 vial, single-use in 1 carton / 3.5 mL in 1 vial, single-use | 72205-183-01 | Novadoz PharmaceuticalsIndia | 27 July 2022 |
| 1 vial, single-dose in 1 carton / 3.5 mL in 1 vial, single-dose | 83090-008-01 | Sintetica | 15 July 2023 |
| 1 vial in 1 carton / 3.5 mL in 1 vial | 70069-836-01 | Somerset Therapeutics | 29 April 2025 |
| 1 vial, single-use in 1 carton / 3.5 mL in 1 vial, single-use | 68001-541-36 | BluePoint Laboratories | 31 July 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Bortezomib
Clinical summary
Bortezomib is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma treatment of adult patients with mantle cell lymphoma Multiple Myeloma VELCADE is indicated for the treatment of adult patients with multiple myeloma. MedsAcross supplies Bortezomib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BortezomibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- VELCADE prescribing information (Takeda Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Velcade: European public assessment report (EPAR) · European Medicines Agency
- Bortezomib Accord: European public assessment report (EPAR) · European Medicines Agency
Need Bortezomib 3.5 mg/3.5 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.